Clinical and bone density outcomes of tumor-induced osteomalacia after treatment

Endocrine Practice

Volumn 13, Issue 5, 2007, Pages 458-462

  Umphrey, Lisa G ^a   Whitaker, Michael D ^a   Bosch, E Peter ^a   Cook, Curtiss B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23;

ARTICLE; BLOOD; BONE DENSITY; CASE REPORT; COMPRESSION FRACTURE; CONVALESCENCE; DISABILITY; HUMAN; MALE; MESENCHYMOMA; MIDDLE AGED; MIXED TUMOR; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMALACIA; PARANEOPLASTIC SYNDROME; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SECRETION; SOFT TISSUE TUMOR;

BONE DENSITY; DISABILITY EVALUATION; FIBROBLAST GROWTH FACTORS; FRACTURES, COMPRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MESENCHYMOMA; MIDDLE AGED; MIXED TUMOR, MALIGNANT; MUSCLE WEAKNESS; OSTEOMALACIA; PARANEOPLASTIC SYNDROMES; POSITRON-EMISSION TOMOGRAPHY; RECOVERY OF FUNCTION; SOFT TISSUE NEOPLASMS;

EID: 35148861713     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.5.458     Document Type: Article

References (11)

1. Carpenter TO. Oncogenic osteomalacia - a complex dance of factors. N Engl J Med. 2003;348:1705-1708.
2. Jan de Beur SM. Tumor-induced osteomalacia. JAMA. 2005;294:1260-1267.
3. Zimering MB, Caldarella FA, White KE, Econs MJ. Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes. Endocr Pract. 2005;11:108-114.
4. Shane E, Parisien M, Henderson JE, et al. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res. 1997;12:1502-1511.
5. Ladha SS, Whitaker MD, Bosch EP. Oncogenic osteomalacia: muscular weakness and multiple fractures. Neurology. 2006;67:364-365.
6. Dupond JL, Mahammedi H, Prié D, et al. Oncogenic osteo malacia: diagnostic implications of fibroblast growth factor 23 and F-18 fluorordeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone. 2005;36:375-378.
7. Berndt TJ, Schiavi S, Kumar R. "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol. 2005;289:F1170-F1182.
8. Econs MJ, Friedman NE, Rowe PS, et al. A PHEX gene mutation is responsible for adult-onset vitamin D-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 1998;83:3459-3462.
9. Rowe PS. The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med. 2004;15:264-281.
10. Imel EA, Peacock M, Pitukcheewanont P, et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2006;91:2055-2061.
11. Nelson AE, Bligh RC, Mirams M, et al. Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab. 2003;88:4088-4094.